187 related articles for article (PubMed ID: 22252658)
21. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
Zemanek T; Melichar B; Lovecek M; Soucek P; Mohelnikova-Duchonova B
Pharmacogenomics; 2019 Jan; 20(2):113-127. PubMed ID: 30539680
[TBL] [Abstract][Full Text] [Related]
22. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications.
Talar-Wojnarowska R; Malecka-Panas E
Med Sci Monit; 2006 Sep; 12(9):RA186-93. PubMed ID: 16940943
[TBL] [Abstract][Full Text] [Related]
23. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
Brunetti O; Russo A; Scarpa A; Santini D; Reni M; Bittoni A; Azzariti A; Aprile G; Delcuratolo S; Signorile M; Gnoni A; Palermo L; Lorusso V; Cascinu S; Silvestris N
Oncotarget; 2015 Sep; 6(27):23323-41. PubMed ID: 26259238
[TBL] [Abstract][Full Text] [Related]
24. Molecular Drivers of Pancreatic Cancer Pathogenesis: Looking Inward to Move Forward.
Khan MA; Azim S; Zubair H; Bhardwaj A; Patel GK; Khushman M; Singh S; Singh AP
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28383487
[TBL] [Abstract][Full Text] [Related]
25. MicroRNAs in Pancreatic Cancer: biomarkers, prognostic, and therapeutic modulators.
Daoud AZ; Mulholland EJ; Cole G; McCarthy HO
BMC Cancer; 2019 Nov; 19(1):1130. PubMed ID: 31752758
[TBL] [Abstract][Full Text] [Related]
26. Pancreatic cancer: updates on translational research and future applications.
Sarris EG; Syrigos KN; Saif MW
JOP; 2013 Mar; 14(2):145-8. PubMed ID: 23474558
[TBL] [Abstract][Full Text] [Related]
27. MicroRNAs in pancreatic ductal adenocarcinoma: new diagnostic and therapeutic clues.
Seux M; Iovanna J; Dagorn JC; Dusetti NJ
Pancreatology; 2009; 9(1-2):66-72. PubMed ID: 19077456
[TBL] [Abstract][Full Text] [Related]
28. An introduction to pancreatic adenocarcinoma genetics, pathology and therapy.
Kern SE; Hruban RH; Hidalgo M; Yeo CJ
Cancer Biol Ther; 2002; 1(6):607-13. PubMed ID: 12642681
[TBL] [Abstract][Full Text] [Related]
29. A review on the role of microRNA in biology, diagnosis, and treatment of pancreatic adenocarcinoma.
Papaconstantinou IG; Lykoudis PM; Gazouli M; Manta A; Polymeneas G; Voros D
Pancreas; 2012 Jul; 41(5):671-7. PubMed ID: 22695087
[TBL] [Abstract][Full Text] [Related]
30. A 6‑gene risk score system constructed for predicting the clinical prognosis of pancreatic adenocarcinoma patients.
Liu Y; Zhu D; Xing H; Hou Y; Sun Y
Oncol Rep; 2019 Mar; 41(3):1521-1530. PubMed ID: 30747226
[TBL] [Abstract][Full Text] [Related]
31. A novel sensitive detection method for DNA methylation in circulating free DNA of pancreatic cancer.
Shinjo K; Hara K; Nagae G; Umeda T; Katsushima K; Suzuki M; Murofushi Y; Umezu Y; Takeuchi I; Takahashi S; Okuno Y; Matsuo K; Ito H; Tajima S; Aburatani H; Yamao K; Kondo Y
PLoS One; 2020; 15(6):e0233782. PubMed ID: 32520974
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review.
Dhayat S; Mardin WA; Mees ST; Haier J
Int J Cancer; 2011 Sep; 129(5):1031-41. PubMed ID: 21413017
[TBL] [Abstract][Full Text] [Related]
33. Preoperative GNAS and KRAS testing in the diagnosis of pancreatic mucinous cysts.
Singhi AD; Nikiforova MN; Fasanella KE; McGrath KM; Pai RK; Ohori NP; Bartholow TL; Brand RE; Chennat JS; Lu X; Papachristou GI; Slivka A; Zeh HJ; Zureikat AH; Lee KK; Tsung A; Mantha GS; Khalid A
Clin Cancer Res; 2014 Aug; 20(16):4381-9. PubMed ID: 24938521
[TBL] [Abstract][Full Text] [Related]
34. Emerging roles of microRNAs in pancreatic cancer diagnosis, therapy and prognosis (Review).
Subramani R; Gangwani L; Nandy SB; Arumugam A; Chattopadhyay M; Lakshmanaswamy R
Int J Oncol; 2015 Oct; 47(4):1203-10. PubMed ID: 26314882
[TBL] [Abstract][Full Text] [Related]
35. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.
Knudsen ES; O'Reilly EM; Brody JR; Witkiewicz AK
Gastroenterology; 2016 Jan; 150(1):48-63. PubMed ID: 26385075
[TBL] [Abstract][Full Text] [Related]
36. Trends in pancreatic adenocarcinoma incidence and mortality in the United States in the last four decades; a SEER-based study.
Saad AM; Turk T; Al-Husseini MJ; Abdel-Rahman O
BMC Cancer; 2018 Jun; 18(1):688. PubMed ID: 29940910
[TBL] [Abstract][Full Text] [Related]
37. Early detection of pancreatic carcinoma.
Rosty C; Goggins M
Hematol Oncol Clin North Am; 2002 Feb; 16(1):37-52. PubMed ID: 12063828
[TBL] [Abstract][Full Text] [Related]
38. Improving pancreatic cancer diagnosis using circulating tumor cells: prospects for staging and single-cell analysis.
Court CM; Ankeny JS; Hou S; Tseng HR; Tomlinson JS
Expert Rev Mol Diagn; 2015; 15(11):1491-504. PubMed ID: 26390158
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic alterations as biomarkers in pancreatic ductal adenocarcinoma.
Syren P; Andersson R; Bauden M; Ansari D
Scand J Gastroenterol; 2017; 52(6-7):668-673. PubMed ID: 28301276
[TBL] [Abstract][Full Text] [Related]
40. ACTN4 copy number increase as a predictive biomarker for chemoradiotherapy of locally advanced pancreatic cancer.
Watanabe T; Ueno H; Watabe Y; Hiraoka N; Morizane C; Itami J; Okusaka T; Miura N; Kakizaki T; Kakuya T; Kamita M; Tsuchida A; Nagakawa Y; Wilber H; Yamada T; Honda K
Br J Cancer; 2015 Feb; 112(4):704-13. PubMed ID: 25602965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
